Imprimis Pharmaceuticals has received approval from the Institutional Review Board (IRB) to initiate Phase III clinical trial protocol of its new topical non-steroidal anti-inflammatory drug (NSAID) candidate, Impracor. Impracor is based ...
Imprimis Pharmaceuticals has announced the completion of clinical trials of Impracor, a topical analgesic cream, which delivers a therapeutic dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study, which was conducted by ...